Literature DB >> 16611911

Diverse effects of cyclosporine on hepatitis C virus strain replication.

Naoto Ishii1, Koichi Watashi, Takayuki Hishiki, Kaku Goto, Daisuke Inoue, Makoto Hijikata, Takaji Wakita, Nobuyuki Kato, Kunitada Shimotohno.   

Abstract

Recently, a production system for infectious particles of hepatitis C virus (HCV) utilizing the genotype 2a JFH1 strain has been developed. This strain has a high capacity for replication in the cells. Cyclosporine (CsA) has a suppressive effect on HCV replication. In this report, we characterize the anti-HCV effect of CsA. We observe that the presence of viral structural proteins does not influence the anti-HCV activity of CsA. Among HCV strains, the replication of genotype 1b replicons was strongly suppressed by treatment with CsA. In contrast, JFH1 replication was less sensitive to CsA and its analog, NIM811. Replication of JFH1 did not require the cellular replication cofactor, cyclophilin B (CyPB). CyPB stimulated the RNA binding activity of NS5B in the genotype 1b replicon but not the genotype 2a JFH1 strain. These findings provide an insight into the mechanisms of diversity governing virus-cell interactions and in the sensitivity of these strains to antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611911      PMCID: PMC1472040          DOI: 10.1128/JVI.80.9.4510-4520.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

Authors:  D R Taylor; S T Shi; P R Romano; G N Barber; M M Lai
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

2.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.

Authors:  Takanobu Kato; Tomoko Date; Michiko Miyamoto; Masaya Sugiyama; Yasuhito Tanaka; Etsuro Orito; Tomoyoshi Ohno; Kanji Sugihara; Izumi Hasegawa; Kei Fujiwara; Kiyoaki Ito; Atsushi Ozasa; Masashi Mizokami; Takaji Wakita
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

5.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

6.  Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1).

Authors:  Michiko Miyamoto; Takanobu Kato; Tomoko Date; Masashi Mizokami; Takaji Wakita
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

7.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.

Authors:  Elena Sokolskaja; David M Sayah; Jeremy Luban
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

View more
  56 in total

1.  NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Authors:  Sue Ma; Joanna E Boerner; ChoiLai TiongYip; Beat Weidmann; Neil S Ryder; Michael P Cooreman; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Cyclosporin A inhibits the replication of diverse coronaviruses.

Authors:  Adriaan H de Wilde; Jessika C Zevenhoven-Dobbe; Yvonne van der Meer; Volker Thiel; Krishna Narayanan; Shinji Makino; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

3.  HCV in liver transplantation.

Authors:  Giacomo Germani; Emmanuel Tsochatzis; Vasilios Papastergiou; Andrew K Burroughs
Journal:  Semin Immunopathol       Date:  2012-07-25       Impact factor: 9.623

Review 4.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 5.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

6.  Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Authors:  Feng Yang; Jason M Robotham; Heather B Nelson; Andre Irsigler; Rachael Kenworthy; Hengli Tang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Authors:  Feng Yang; Jason M Robotham; Henry Grise; Stephen Frausto; Vanesa Madan; Margarita Zayas; Ralf Bartenschlager; Margaret Robinson; Andrew E Greenstein; Anita Nag; Timothy M Logan; Ewa Bienkiewicz; Hengli Tang
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

Review 8.  Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.

Authors:  Jérôme Dumortier; Olivier Boillot; Jean-Yves Scoazec
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.

Authors:  Hitoshi Suzuki; Norihiko Matsumoto; Tomoyuki Suzuki; Myint Oo Chang; Hiroshi Takaku
Journal:  Virol J       Date:  2009-10-02       Impact factor: 4.099

10.  Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.

Authors:  Fiona Fernandes; Israr-ul H Ansari; Rob Striker
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.